Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease

Progress in Neurobiology

Volumn 155, Issue , 2017, Pages 96-119

  Zucca, Fabio A ^a   Segura Aguilar, Juan ^b   Ferrari, Emanuele ^a   Muñoz, Patricia ^b   Paris, Irmgard ^b,c   Sulzer, David ^d   Sarna, Tadeusz ^e   Casella, Luigi ^f   Zecca, Luigi ^a  

^a INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSIDAD SANTO TOMÁS   (Chile)

^d NewYork Presbyterian Hospital   (United States)

^e JAGIELLONIAN UNIVERSITY   (Poland)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

Dopamine; Human neuromelanin; Iron; Melanin; Parkinson's disease

Indexed keywords

DOPAMINE; IRON; IRON DERIVATIVE; NEUROMELANIN; MELANIN;

BIOCHEMISTRY; COGNITIVE AGING; DEGENERATIVE DISEASE; DRUG CLASSIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IRON METABOLISM; NEUROPROTECTION; NONHUMAN; OXIDATION; PARKINSON DISEASE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; AGING; ANIMAL; METABOLISM;

AGING; ANIMALS; DOPAMINE; HUMANS; IRON; MELANINS; PARKINSON DISEASE;

EID: 84952845727     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2015.09.012     Document Type: Review

References (345)

1. Abbas, N., Lücking, C.B., Ricard, S., Dürr, A., Bonifati, V., De Michele, G., Bouley, S., Vaughan, J.R., Gasser, T., Marconi, R., Broussolle, E., Brefel-Courbon, C., Harhangi, B.S., Oostra, B.A., Fabrizio, E., Böhme, G.A., Pradier, L., Wood, N.W., Filla, A., Meco, G., Denefle, P., Agid, Y., Brice, A., A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum. Mol. Genet. 8 (1999), 567–574.
2. Abbott, N.J., Rönnbäck, L., Hansson, E., Astrocyte-endothelial interactions at the blood–brain barrier. Nat. Rev. Neurosci. 7 (2006), 41–53.
3. Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R., Begley, D.J., Structure and function of the blood–brain barrier. Neurobiol. Dis. 37 (2010), 13–25.
4. Abdel-Malek, Z., Kadekaro, A.L., Human pigmentation: its regulation by ultraviolet light and by endocrine, paracrine and autocrine factors. Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.-P., (eds.) The Pigmentary System: Physiology and Pathophysiology, second edition, 2006, Blackwell Publishing, Malden, MA, USA, 410–420.
5. Agrup, G., Hansson, C., Rorsman, H., Rosengren, E., The effect of cysteine on oxidation of tyrosine, dopa, and cysteinyldopas. Arch. Dermatol. Res. 272 (1982), 103–115.
6. Aguirre, P., Urrutia, P., Tapia, V., Villa, M., Paris, I., Segura-Aguilar, J., Núñez, M.T., The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1. Biometals 25 (2012), 795–803.
7. Aime, S., Bergamasco, B., Biglino, D., Digilio, G., Fasano, M., Giamello, E., Lopiano, L., EPR investigations of the iron domain in neuromelanin. Biochim. Biophys. Acta 1361 (1997), 49–58.
8. 13C-NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with Parkinson's disease. Mov. Disord. 15 (2000), 977–981.
9. Aisen, P., Enns, C., Wessling-Resnick, M., Chemistry and biology of eukaryotic iron metabolism. Int. J. Biochem. Cell Biol. 33 (2001), 940–959.
10. Anand, U., Mukherjee, S., Binding, unfolding and refolding dynamics of serum albumins. Biochim. Biophys. Acta 1830 (2013), 5394–5404.
11. Andersen, H.H., Johnsen, K.B., Moos, T., Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration. Cell Mol. Life Sci. 71 (2014), 1607–1622.
12. Anderson, D.G., Mariappan, S.V., Buettner, G.R., Doorn, J.A., Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. J. Biol. Chem. 286 (2011), 26978–26986.
13. Andrews, N.C., Molecular control of iron metabolism. Best Pract. Res. Clin. Haematol. 18 (2005), 159–169.
14. Andrews, N.C., Forging a field: the golden age of iron biology. Blood 112 (2008), 219–230.
15. Arreguin, S., Nelson, P., Padway, S., Shirazi, M., Pierpont, C., Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease. J. Inorg. Biochem. 103 (2009), 87–93.
16. Arriagada, C., Paris, I., Sanchez de las Matas, M.J., Martinez-Alvarado, P., Cardenas, S., Castañeda, P., Graumann, R., Perez-Pastene, C., Olea-Azar, C., Couve, E., Herrero, M.T., Caviedes, P., Segura-Aguilar, J., On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiol. Dis. 16 (2004), 468–477.
17. Ayton, S., Lei, P., Duce, J.A., Wong, B.X., Sedjahtera, A., Adlard, P.A., Bush, A.I., Finkelstein, D.I., Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann. Neurol. 73 (2013), 554–559.
18. Badaracco, M.E., Siri, M.V., Pasquini, J.M., Oligodendrogenesis: the role of iron. Biofactors 36 (2010), 98–102.
19. Baez, S., Segura-Aguilar, J., Widersten, M., Johansson, A.S., Mannervik, B., Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem. J. 324 (1997), 25–28.
20. Ballard, P.A., Tetrud, J.W., Langston, J.W., Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35 (1985), 949–956.
21. Banati, R.B., Daniel, S.E., Blunt, S.B., Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 13 (1998), 221–227.
22. Beach, T.G., Sue, L.I., Walker, D.G., Lue, L.F., Connor, D.J., Caviness, J.N., Sabbagh, M.N., Adler, C.H., Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol. 114 (2007), 419–424.
23. Beard, J., Iron deficiency alters brain development and functioning. J. Nutr. 133 (2003), 1468S–1472S.
24. Beard, J.L., Chen, Q., Connor, J., Jones, B.C., Altered monamine metabolism in caudate-putamen of iron-deficient rats. Pharmacol. Biochem. Behav. 48 (1994), 621–624.
25. Ben-Shachar, D., Riederer, P., Youdim, M.B., Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57 (1991), 1609–1614.
26. Bianco, L.E., Wiesinger, J., Earley, C.J., Jones, B.C., Beard, J.L., Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats. J. Neurochem. 106 (2008), 205–215.
27. Bisaglia, M., Mammi, S., Bubacco, L., Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J. Biol. Chem. 282 (2007), 15597–15605.
28. Bisaglia, M., Soriano, M.E., Arduini, I., Mammi, S., Bubacco, L., Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim. Biophys. Acta 1802 (2010), 699–706.
29. Bissantz, C., Kuhn, B., Stahl, M., A medicinal chemist's guide to molecular interactions. J. Med. Chem. 53 (2010), 5061–5084.
30. Block, M.L., Zecca, L., Hong, J.S., Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8 (2007), 57–69.
31. Bohic, S., Murphy, K., Paulus, W., Cloetens, P., Salomé, M., Susini, J., Double, K., Intracellular chemical imaging of the developmental phases of human neuromelanin using synchrotron X-ray microspectroscopy. Anal. Chem. 80 (2008), 9557–9566.
32. Boissy, R.E., Hornyak, T.J., Extracutaneous melanocytes. Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.-P., (eds.) The Pigmentary System: Physiology and Pathophysiology, second edition, 2006, Blackwell Publishing, Malden, MA, USA, 91–107.
33. Bolzoni, F., Giraudo, S., Lopiano, L., Bergamasco, B., Fasano, M., Crippa, P.R., Magnetic investigations of human mesencephalic neuromelanin. Biochim. Biophys. Acta 1586 (2002), 210–218.
34. Bonifati, V., Rizzu, P., van Baren, M.J., Schaap, O., Breedveld, G.J., Krieger, E., Dekker, M.C., Squitieri, F., Ibanez, P., Joosse, M., van Dongen, J.W., Vanacore, N., van Swieten, J.C., Brice, A., Meco, G., van Duijn, C.M., Oostra, B.A., Heutink, P., Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003), 256–259.
35. Borie, C., Gasparini, F., Verpillat, P., Bonnet, A.M., Agid, Y., Hetet, G., Brice, A., Dürr, A., Grandchamp, B., French Parkinson's disease genetic study group, Association study between iron-related genes polymorphisms and Parkinson's disease. J. Neurol. 249 (2002), 801–804.
36. Boulton, M.E., Melanin and the retinal pigment epithelium. Marmor, M.F., Wolfensberger, T.J., (eds.) The Retinal Pigment Epithelium, 1998, Oxford University Press, New York, 68–85.
37. Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A., Jansen Steur, E.N., Braak, E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003), 197–211.
38. Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., Del Tredici, K., Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318 (2004), 121–134.
39. Bradbury, M.W., Transport of iron in the blood–brain–cerebrospinal fluid system. J. Neurochem. 69 (1997), 443–454.
40. Brenner, M., Hearing, V.J., The protective role of melanin against UV damage in human skin. Photochem. Photobiol. 84 (2008), 539–849.
41. Bridelli, M.G., Tampellini, D., Zecca, L., The structure of neuromelanin and its iron binding site studied by infrared spectroscopy. FEBS Lett. 457 (1999), 18–22.
42. Brilliant, M.H., Molecular regulation of melanin formation: melanosome transport proteins. Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.-P., (eds.) The Pigmentary System: Physiology and Pathophysiology, second edition, 2006, Blackwell Publishing, Malden, MA, USA, 230–241.
43. Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.M., Duyckaerts, C., Flavell, R.A., Hirsch, E.C., Hunot, S., Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Investig. 119 (2009), 182–192.
44. Burhans, M.S., Dailey, C., Beard, Z., Wiesinger, J., Murray-Kolb, L., Jones, B.C., Beard, J.L., Iron deficiency: differential effects on monoamine transporters. Nutr. Neurosci. 8 (2005), 31–38.
45. Bush, V.J., Moyer, T.P., Batts, K.P., Parisi, J.E., Essential and toxic element concentrations in fresh and formalin-fixed human autopsy tissues. Clin. Chem. 41 (1995), 284–294.
46. Bush, W.D., Garguilo, J., Zucca, F.A., Albertini, A., Zecca, L., Edwards, G.S., Nemanich, R.J., Simon, J.D., The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 4785–4789.
47. Bush, W.D., Garguilo, J., Zucca, F.A., Bellei, C., Nemanich, R.J., Edwards, G.S., Zecca, L., Simon, J.D., Neuromelanins isolated from different regions of the human brain exhibit a common surface photoionization threshold. Photochem. Photobiol. 85 (2009), 387–890.
48. Burke, W.J., Kumar, V.B., Pandey, N., Panneton, W.M., Gan, Q., Franko, M.W., O'Dell, M., Li, S.W., Pan, Y., Chung, H.D., Galvin, J.E., Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 115 (2008), 193–203.
49. Byers, H.R., Melanosome processing in keratinocytes. Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.-P., (eds.) The Pigmentary System: Physiology and Pathophysiology, second edition, 2006, Blackwell Publishing, Malden, MA, USA, 181–190.
50. Carstam, R., Brinck, C., Hindemith-Augustsson, A., Rorsman, H., Rosengren, E., The neuromelanin of the human substantia nigra. Biochim. Biophys. Acta 1097 (1991), 152–160.
51. Castellani, R.J., Siedlak, S.L., Perry, G., Smith, M.A., Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. 100 (2000), 111–114.
52. Catalá, A., Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem. Phys. Lipids 157 (2009), 1–11.
53. Caviedes, P., Segura-Aguilar, J., The price of development in Chile: overcoming environmental hazards produced by heavy industrial exploitation. Neuroreport, 12, 2001, A25.
54. Cebrián, C., Zucca, F.A., Mauri, P., Steinbeck, J.A., Studer, L., Scherzer, C.R., Kanter, E., Budhu, S., Mandelbaum, J., Vonsattel, J.P., Zecca, L., Loike, J.D., Sulzer, D., MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat. Commun., 5, 2014, 3633.
55. Cheepsunthorn, P., Radov, L., Menzies, S., Reid, J., Connor, J.R., Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain. Glia 35 (2001), 53–62.
56. Cheng, F.C., Kuo, J.S., Chia, L.G., Dryhurst, G., Elevated 5-S cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. J. Neural Transm. 103 (1996), 433–446.
57. Cheng, J., Moss, S.C., Eisner, M., Zschack, P., X-ray characterization of melanins–I. Pigment Cell Res. 7 (1994), 255–262.
58. Cheng, J., Moss, S.C., Eisner, M., X-ray characterization of melanins–II. Pigment Cell Res. 7 (1994), 263–273.
59. Clancy, C.M., Nofsinger, J.B., Hanks, R.K., Simon, J.D., A hierarchical self-assembly of eumelanin. J. Phys. Chem. B 104 (2000), 7871–7873.
60. Conde, J.R., Streit, W.J., Microglia in the aging brain. J. Neuropathol. Exp. Neurol. 65 (2006), 199–203.
61. Connor, J.R., Menzies, S.L., Cellular management of iron in the brain. J. Neurol. Sci. 134:Suppl. (1995), 33–44.
62. Connor, J.R., Menzies, S.L., St Martin, S.M., Mufson, E.J., Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 27 (1990), 595–611.
63. Connor, J.R., Snyder, B.S., Arosio, P., Loeffler, D.A., LeWitt, P., A quantitative analysis of isoferritins in select regions of aged, Parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65 (1995), 717–724.
64. Crichton, R.R., Inorganic Biochemistry of Iron Metabolism from Molecular Mechanisms to Clinical Consequences. 2009, John Wiley & Sons, Chichester, 461.
65. Crichton, R.R., Ward, R.J., Metal Based Neurodegeneration: From Molecular Mechanisms to Therapeutic Strategies. second edition, 2014, John Wiley & Sons, Chichester.
66. Crichton, R.R., Dexter, D.T., Ward, R.J., Brain iron metabolism and its perturbation in neurological diseases. J. Neural Transm. 118 (2011), 301–314.
67. Crippa, P.R., Eisner, M., Morante, S., Stellato, F., Vicentin, F.C., Zecca, L., An XAS study of the sulfur environment in human neuromelanin and its synthetic analogs. Eur. Biophys. J. 39 (2010), 959–970.
68. Cuevas, C., Huenchuguala, S., Muñoz, P., Villa, M., Paris, I., Mannervik, B., Segura-Aguilar, J., Glutathione transferase-M2-2 secreted from glioblastoma cell protects SH-SY5Y cells from aminochrome neurotoxicity. Neurotox. Res. 27 (2015), 217–228.
69. Dagnino-Subiabre, A., Cassels, B.K., Baez, S., Johansson, A.S., Mannervik, B., Segura-Aguilar, J., Glutathione transferase M2-2 catalyzes conjugation of dopamine and dopa o-quinones. Biochem. Biophys. Res. Commun. 274 (2000), 32–36.
70. Dalle-Donne, I., Giustarini, D., Colombo, R., Rossi, R., Milzani, A., Protein carbonylation in human diseases. Trends Mol. Med. 9 (2003), 169–176.
71. Dalle-Donne, I., Rossi, R., Giustarini, D., Milzani, A., Colombo, R., Protein carbonyl groups as biomarkers of oxidative stress. Clin. Chim. Acta 329 (2003), 23–38.
72. D'Amato, R.J., Lipman, Z.P., Snyder, S.H., Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231 (1986), 987–989.
73. Dexter, D.T., Wells, F.R., Agid, F., Agid, Y., Lees, A.J., Jenner, P., Marsden, C.D., Increased nigral iron content in postmortem parkinsonian brain. Lancet 2 (1987), 1219–1220.
74. Dexter, D.T., Wells, F.R., Lees, A.J., Agid, F., Agid, Y., Jenner, P., Marsden, C.D., Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem., 52, 1989, 1830.
75. Dexter, D.T., Carayon, A., Vidailhet, M., Ruberg, M., Agid, F., Agid, Y., Lees, A.J., Wells, F.R., Jenner, P., Marsden, C.D., Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55 (1990), 16–20.
76. Dexter, D.T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells, F.R., Daniel, S.E., Lees, A.J., Jenner, P., Marsden, C.D., Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 (1991), 1953–1975.
77. Dibenedetto, D., Rossetti, G., Caliandro, R., Carloni, P., A molecular dynamics simulation-based interpretation of nuclear magnetic resonance multidimensional heteronuclear spectra of α synuclein dopamine adducts. Biochemistry 52 (2013), 6672–6683.
78. Di Donato, P., Napolitano, A., 1,4-benzothiazines as key intermediates in the biosynthesis of red hair pigment pheomelanins. Pigment Cell Res. 16 (2003), 532–539.
79. d'Ischia, M., Wakamatsu, K., Napolitano, A., Briganti, S., Garcia-Borron, J.C., Kovacs, D., Meredith, P., Pezzella, A., Picardo, M., Sarna, T., Simon, J.D., Ito, S., Melanins and melanogenesis: methods, standards, protocols. Pigment Cell Melanoma Res. 26 (2013), 616–633.
80. d'Ischia, M., Napolitano, A., Ball, V., Chen, C.T., Buehler, M.J., Polydopamine and eumelanin: from structure-property relationships to a unified tailoring strategy. Acc. Chem. Res. 47 (2014), 3541–3550.
81. Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S., Morrison, B. 3rd, Stockwell, B.R., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (2012), 1060–1072.
82. Dlouhy, A.C., Outten, C.E., The iron metallome in eukaryotic organisms. Met. Ions Life Sci. 12 (2013), 241–278.
83. Double, K.L., Zecca, L., Costi, P., Mauer, M., Griesinger, C., Ito, S., Ben-Shachar, D., Bringmann, G., Fariello, R.G., Riederer, P., Gerlach, M., Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J. Neurochem. 75 (2000), 2583–2589.
84. Double, K.L., Gerlach, M., Schünemann, V., Trautwein, A.X., Zecca, L., Gallorini, M., Youdim, M.B., Riederer, P., Ben-Shachar, D., Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 66 (2003), 489–494.
85. Dzierzega-Lecznar, A., Kurkiewicz, S., Stepien, K., Chodurek, E., Riederer, P., Gerlach, M., Structural investigations of neuromelanin by pyrolysis-gas chromatography/mass spectrometry. J. Neural Transm. 113 (2006), 729–734.
86. Earle, K.M., Studies on Parkinson's disease including X-ray fluorescent spectroscopy of formalin fixed brain tissue. J. Neuropathol. Exp. Neurol. 27 (1968), 1–14.
87. Ebrahimi-Fakhari, D., Wahlster, L., McLean, P.J., Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol. 124 (2012), 153–172.
88. Ebrahimi-Fakhari, D., McLean, P.J., Unni, V.K., Alpha-synuclein's degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease. Autophagy 8 (2012), 281–283.
89. Eisenhofer, G., Kopin, I.J., Goldstein, D.S., Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 56 (2004), 331–349.
90. el-Agnaf, O.M., Irvine, G.B., Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans. 30 (2002), 559–565.
91. Engelen, M., Vanna, R., Bellei, C., Zucca, F.A., Wakamatsu, K., Monzani, E., Ito, S., Casella, L., Zecca, L., Neuromelanins of human brain have soluble and insoluble components with dolichols attached to the melanic structure. PLoS ONE, 7, 2012, e48490.
92. Enochs, W.S., Nilges, M.J., Swartz, H.M., Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy. J. Neurochem. 61 (1993), 68–79.
93. Esterbauer, H., Schaur, R.J., Zollner, H., Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11 (1991), 81–128.
94. Exley, C., House, E., Polwart, A., Esiri, M.M., Brain burdens of aluminum, iron, and copper and their relationships with amyloid-β pathology in 60 human brains. J. Alzheimers Dis. 31 (2012), 725–730.
95. Exner, N., Lutz, A.K., Haass, C., Winklhofer, K.F., Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 31 (2012), 3038–3062.
96. Farrall, A.J., Wardlaw, J.M., Blood–brain barrier: ageing and microvascular disease – systematic review and meta-analysis. Neurobiol. Aging 30 (2009), 337–352.
97. Fasano, M., Bergamasco, B., Lopiano, L., Modifications of the iron-neuromelanin system in Parkinson's disease. J. Neurochem. 96 (2006), 909–916.
98. Faucheux, B.A., Nillesse, N., Damier, P., Spik, G., Mouatt-Prigent, A., Pierce, A., Leveugle, B., Kubis, N., Hauw, J.J., Agid, Y., et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 9603–9607.
99. Faucheux, B.A., Bonnet, A.M., Agid, Y., Hirsch, E.C., Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353 (1999), 981–982.
100. Faucheux, B.A., Martin, M.E., Beaumont, C., Hunot, S., Hauw, J.J., Agid, Y., Hirsch, E.C., Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 83 (2002), 320–330.
101. Faucheux, B.A., Martin, M.E., Beaumont, C., Hauw, J.J., Agid, Y., Hirsch, E.C., Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 86 (2003), 1142–1148.
102. Fedorow, H., Pickford, R., Hook, J.M., Double, K.L., Halliday, G.M., Gerlach, M., Riederer, P., Garner, B., Dolichol is the major lipid component of human substantia nigra neuromelanin. J. Neurochem. 92 (2005), 990–995.
103. Felix, C.C., Hyde, J.S., Sarna, T., Sealy, R.C., Interactions of melanin with metal ions. Electron spin resonance evidence for chelate complexes of metal ions with free radicals. J. Am. Chem. Soc. 100 (1978), 3922–3926.
104. Ferrari, E., Engelen, M., Monzani, E., Sturini, M., Girotto, S., Bubacco, L., Zecca, L., Casella, L., Synthesis and structural characterization of soluble neuromelanin analogs provides important clues to its biosynthesis. J. Biol. Inorg. Chem. 18 (2013), 81–93.
105. Flydal, M.I., Martinez, A., Phenylalanine hydroxylase: function, structure, and regulation. IUBMB Life 65 (2013), 341–349.
106. Foppoli, C., Coccia, R., Cini, C., Rosei, M.A., Catecholamines oxidation by xanthine oxidase. Biochim. Biophys. Acta 1334 (1997), 200–206.
107. Fuentes, P., Paris, I., Nassif, M., Caviedes, P., Segura-Aguilar, J., Inhibition of VMAT-2 and DT-diaphorase induce cell death in a substantia nigra-derived cell line – an experimental cell model for dopamine toxicity studies. Chem. Res. Toxicol. 20 (2007), 776–783.
108. Gałazka-Friedman, J., Bauminger, E.R., Friedman, A., Barcikowska, M., Hechel, D., Nowik, I., Iron in parkinsonian and control substantia nigra – a Mössbauer spectroscopy study. Mov. Disord. 11 (1996), 8–16.
109. Gallas, J.M., Littrell, K.C., Seifert, S., Zajac, G.W., Thiyagarajan, P., Solution structure of copper ion-induced molecular aggregates of tyrosine melanin. Biophys. J. 77 (1999), 1135–1142.
110. Galzigna, L., Schiappelli, M.P., Rigo, A., Scarpa, M., A rat brain fraction and different purified peroxidases catalyzing the formation of dopaminochrome from dopamine. Biochim. Biophys. Acta 1427 (1999), 329–336.
111. Galzigna, L., De Iuliis, A., Zanatta, L., Enzymatic dopamine peroxidation in substantia nigra of human brain. Clin. Chim. Acta 300 (2000), 131–138.
112. Gao, H.M., Hong, J.S., Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 29 (2008), 357–365.
113. García-Borrón, J.C., Solano, F., Molecular anatomy of tyrosinase and its related proteins: beyond the histidine-bound metal catalytic center. Pigment Cell Res. 15 (2002), 162–173.
114. Gerlach, M., Trautwein, A.X., Zecca, L., Youdim, M.B., Riederer, P., Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J. Neurochem. 65 (1995), 923–926.
115. Gibb, W.R., Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res. 581 (1992), 283–291.
116. Goedert, M., Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2 (2001), 492–501.
117. Goldstein, D.S., Sullivan, P., Holmes, C., Miller, G.W., Alter, S., Strong, R., Mash, D.C., Kopin, I.J., Sharabi, Y., Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J. Neurochem. 126 (2013), 591–603.
118. Goldstein, D.S., Kopin, I.J., Sharabi, Y., Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol. Ther. 144 (2014), 268–282.
119. Good, P.F., Olanow, C.W., Perl, D.P., Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593 (1992), 343–346.
120. Greco, G., Panzella, L., Gentile, G., Errico, M.E., Carfagna, C., Napolitano, A., d'Ischia, M., A melanin-inspired pro-oxidant system for dopa(mine) polymerization: mimicking the natural casing process. Chem. Commun. (Camb.) 47 (2011), 10308–10310.
121. Greenwald, J., Riek, R., Biology of amyloid: structure, function, and regulation. Structure 18 (2010), 1244–1260.
122. Griffiths, P.D., Dobson, B.R., Jones, G.R., Clarke, D.T., Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 122 (1999), 667–673.
123. Guerreiro, R.J., Bras, J.M., Santana, I., Januario, C., Santiago, B., Morgadinho, A.S., Ribeiro, M.H., Hardy, J., Singleton, A., Oliveira, C., Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol., 6, 2006, 24.
124. Hallgren, B., Sourander, P., The effect of age on the non-haemin iron in the human brain. J. Neurochem. 3 (1958), 41–51.
125. Halprin, K.M., Epidermal “turnover time” – a re-examination. Br. J. Dermatol. 86 (1972), 14–19.
126. Hare, D.J., Gerlach, M., Riederer, P., Considerations for measuring iron in post-mortem tissue of Parkinson's disease patients. J. Neural Transm. 119 (2012), 1515–1521.
127. Hare, D.J., Lei, P., Ayton, S., Roberts, B.R., Grimm, R., George, J.L., Bishop, D.P., Beavis, A.D., Donovan, S.J., McColl, G., Volitakis, I., Masters, C.L., Adlard, P.A., Cherny, R.A., Bush, A.I., Finkelstein, D.I., Doble, P.A., An iron-dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. Chem. Sci. 5 (2014), 2160–2169.
128. Hashimoto, M., Hsu, L.J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., Masliah, E., Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10 (1999), 717–721.
129. Hastings, T.G., Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64 (1995), 919–924.
130. Hattori, N., Sato, S., Animal models of Parkinson's disease: similarities and differences between the disease and models. Neuropathology 27 (2007), 479–483.
131. Hattori, N., Kitada, T., Matsumine, H., Asakawa, S., Yamamura, Y., Yoshino, H., Kobayashi, T., Yokochi, M., Wang, M., Yoritaka, A., Kondo, T., Kuzuhara, S., Nakamura, S., Shimizu, N., Mizuno, Y., Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann. Neurol. 44 (1998), 935–941.
132. Hauser, D.N., Hastings, T.G., Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol. Dis. 51 (2013), 35–42.
133. Hauser, D.N., Dukes, A.A., Mortimer, A.D., Hastings, T.G., Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4. Free Radic. Biol. Med. 65 (2013), 419–427.
134. Hawkes, C.H., Del Tredici, K., Braak, H., A timeline for Parkinson's disease. Parkinsonism Relat. Disord. 16 (2010), 79–84.
135. Hearing, V.J., The regulation of melanin formation. Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.-P., (eds.) The Pigmentary System: Physiology and Pathophysiology, second edition, 2006, Blackwell Publishing, Malden, MA, USA, 191–212.
136. Hebbrecht, G., Maenhaut, W., De Reuck, J., Brain trace elements and aging. Nucl. Instrum. Methods Phys. Res. B 150 (1999), 208–213.
137. Hentze, M.W., Muckenthaler, M.U., Galy, B., Camaschella, C., Two to tango: regulation of Mammalian iron metabolism. Cell 142 (2010), 24–38.
138. Hirsch, E., Graybiel, A.M., Agid, Y.A., Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 (1988), 345–348.
139. Hochstrasser, H., Bauer, P., Walter, U., Behnke, S., Spiegel, J., Csoti, I., Zeiler, B., Bornemann, A., Pahnke, J., Becker, G., Riess, O., Berg, D., Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63 (2004), 1912–1917.
140. House, E., Collingwood, J., Khan, A., Korchazkina, O., Berthon, G., Exley, C., Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J. Alzheimers Dis. 6 (2004), 291–301.
141. House, E., Esiri, M., Forster, G., Ince, P.G., Exley, C., Aluminium, iron and copper in human brain tissues donated to the Medical Research Council's Cognitive Function and Ageing Study. Metallomics 4 (2012), 56–65.
142. Huenchuguala, S., Muñoz, P., Zavala, P., Villa, M., Cuevas, C., Ahumada, U., Graumann, R., Nore, B.F., Couve, E., Mannervik, B., Paris, I., Segura-Aguilar, J., Glutathione transferase mu 2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction. Autophagy 10 (2014), 618–630.
143. Ikemoto, K., Nagatsu, I., Ito, S., King, R.A., Nishimura, A., Nagatsu, T., Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra?. Neurosci. Lett. 253 (1998), 198–200.
144. Inoue, K., Ito, S., Kimura, E., Nabeshima, M., Takayama, M., Ishii, T., Chemical analysis of melanin in Guinea pig inner ear. Ear Res. Japan 16 (1984), 68–71.
145. Ito, S., Encapsulation of a reactive core in neuromelanin. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 14647–14648.
146. Ito, S., Wakamatsu, K., Chemistry of melanins. Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.-P., (eds.) The Pigmentary System: Physiology and Pathophysiology, second edition, 2006, Blackwell Publishing, Malden, MA, USA, 282–310.
147. Ito, S., Wakamatsu, K., Chemistry of mixed melanogenesis – pivotal roles of dopaquinone. Photochem. Photobiol. 84 (2008), 582–592.
148. Ito, S., Pilat, A., Gerwat, W., Skumatz, C.M., Ito, M., Kiyono, A., Zadlo, A., Nakanishi, Y., Kolbe, L., Burke, J.M., Sarna, T., Wakamatsu, K., Photoaging of human retinal pigment epithelium is accompanied by oxidative modifications of its eumelanin. Pigment Cell Melanoma Res. 26 (2013), 357–366.
149. Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., Youdim, M.B., Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Park. Dis. Dement. Sect. 2 (1990), 327–340.
150. Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben-Shachar, D., Youdim, M.B., Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59 (1992), 1168–1171.
151. Jimbow, K., Quevedo, W.C., Fitzpatrick, T.B., Szabo, G., Biology of melanocytes. Freeberg, I.A., Eisen, A.Z., Wolf, K., Austen, K.F., Goldsimth, L.A., Katz, S.I., Fitzpatrick, T.B., (eds.) Fiotzpatrick's Dermatology in General Medicine, fifth edition, 1999, McGraw Hill, New York, 192–220.
152. Jimenez, M., Garcia-Carmona, F., Garcia-Canovas, F., Iborra, J.L., Lozano, J.A., Martinez, F., Chemical intermediates in dopamine oxidation by tyrosinase, and kinetic studies of the process. Arch. Biochem. Biophys. 235 (1984), 438–448.
153. Kachergus, J., Mata, I.F., Hulihan, M., Taylor, J.P., Lincoln, S., Aasly, J., Gibson, J.M., Ross, O.A., Lynch, T., Wiley, J., Payami, H., Nutt, J., Maraganore, D.M., Czyzewski, K., Styczynska, M., Wszolek, Z.K., Farrer, M.J., Toft, M., Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76 (2005), 672–680.
154. Kaczara, P., Zaręba, M., Herrnreiter, A., Skumatz, C.M., Ządło, A., Sarna, T., Burke, J.M., Melanosome-iron interactions within retinal pigment epithelium-derived cells. Pigment Cell Melanoma Res. 25 (2012), 804–814.
155. Kakhlon, O., Cabantchik, Z.I., The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic. Biol. Med. 33 (2002), 1037–1046.
156. Kalia, L.V., Kalia, S.K., McLean, P.J., Lozano, A.M., Lang, A.E., α-Synuclein oligomers and clinical implications for Parkinson disease. Ann. Neurol. 73 (2013), 155–169.
157. Karlsson, O., Lindquist, N.G., Melanin affinity and its possible role in neurodegeneration. J. Neural Transm. 120 (2013), 1623–1630.
158. Kastner, A., Hirsch, E.C., Lejeune, O., Javoy-Agid, F., Rascol, O., Agid, Y., Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?. J. Neurochem. 59 (1992), 1080–1089.
159. Ke, Y., Qian, Z.M., Brain iron metabolism: neurobiology and neurochemistry. Prog. Neurobiol. 83 (2007), 149–173.
160. Kolberg, M., Strand, K.R., Graff, P., Andersson, K.K., Structure, function, and mechanism of ribonucleotide reductases. Biochim. Biophys. Acta 1699 (2004), 1–34.
161. Kollias, N., Sayre, R.M., Zeise, L., Chedekel, M.R., Photoprotection by melanin. J. Photochem. Photobiol. B 9 (1991), 135–160.
162. Kortekaas, R., Leenders, K.L., van Oostrom, J.C., Vaalburg, W., Bart, J., Willemsen, A.T., Hendrikse, N.H., Blood–brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 57 (2005), 176–179.
163. Korytowski, W., Sarna, T., Zareba, M., Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation. Arch. Biochem. Biophys. 319 (1995), 142–148.
164. Kropf, A.J., Bunker, B.A., Eisner, M., Moss, S.C., Zecca, L., Stroppolo, A., Crippa, P.R., X-ray absorption fine-structure spectroscopy studies of Fe sites in natural human neuromelanin and synthetic analogues. Biophys. J. 75 (1998), 3135–3142.
165. Kruszewski, M., Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat. Res. 531 (2003), 81–92.
166. Kwok, J.B., Role of epigenetics in Alzheimer's and Parkinson's disease. Epigenomics 2 (2010), 671–682.
167. Langston, J.W., Forno, L.S., Tetrud, J., Reeves, A.G., Kaplan, J.A., Karluk, D., Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine exposure. Ann. Neurol. 46 (1999), 598–605.
168. LaVoie, M.J., Ostaszewski, B.L., Weihofen, A., Schlossmacher, M.G., Selkoe, D.J., Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11 (2005), 1214–1221.
169. Lhermitte, J., Kraus, W.M., McAlpine, D., Original Papers: On the occurrence of abnormal deposits of iron in the brain in parkinsonism with special reference to its localisation. J. Neurol. Psychopathol. 5 (1924), 195–208.
170. Li, W.J., Jiang, H., Song, N., Xie, J.X., Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells. Neurosci. Bull. 26 (2010), 205–210.
171. Liang, C.L., Nelson, O., Yazdani, U., Pasbakhsh, P., German, D.C., Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J. Comp. Neurol. 473 (2004), 97–106.
172. Lindquist, N.G., Larsson, B.S., Lydén-Sokolowski, A., Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: accumulation in neuromelanin. Neurosci. Lett. 93 (1988), 1–6.
173. Linert, W., Herlinger, E., Jameson, R.F., Kienzl, E., Jellinger, K., Youdim, M.B., Dopamine, 6-hydroxydopamine, iron, and dioxygen – their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316 (1996), 160–168.
174. Liu, Y., Edwards, R.H., The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20 (1997), 125–156.
175. Liu, Y., Simon, J.D., The effect of preparation procedures on the morphology of melanin from the ink sac of Sepia officinalis. Pigment Cell Res. 16 (2003), 72–80.
176. Liu, Y., Simon, J.D., Metal-ion interactions and the structural organization of Sepia eumelanin. Pigment Cell Res. 18 (2005), 42–48.
177. Liu, Y., Hong, L., Kempf, V.R., Wakamatsu, K., Ito, S., Simon, J.D., Ion-exchange and adsorption of Fe(III) by Sepia melanin. Pigment Cell Res. 17 (2004), 262–269.
178. Liu, Y., Hong, L., Wakamatsu, K., Ito, S., Adhyaru, B., Cheng, C.Y., Bowers, C.R., Simon, J.D., Comparison of structural and chemical properties of black and red human hair melanosomes. Photochem. Photobiol. 81 (2005), 135–144.
179. Lopes, K.O., Sparks, D.L., Streit, W.J., Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity. Glia 56 (2008), 1048–1060.
180. Lopiano, L., Chiesa, M., Digilio, G., Giraudo, S., Bergamasco, B., Torre, E., Fasano, M., Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. Biochim. Biophys. Acta 1500 (2000), 306–312.
181. Lozano, J., Muñoz, P., Nore, B.F., Ledoux, S., Segura-Aguilar, J., Stable expression of short interfering RNA for DT-diaphorase induces neurotoxicity. Chem. Res. Toxicol. 23 (2010), 1492–1496.
182. Makin, O.S., Serpell, L.C., Structures for amyloid fibrils. FEBS J. 272 (2005), 5950–5961.
183. Manini, P., Panzella, L., Napolitano, A., d'Ischia, M., Oxidation chemistry of norepinephrine: partitioning of the O-quinone between competing cyclization and chain breakdown pathways and their roles in melanin formation. Chem. Res. Toxicol. 20 (2007), 1549–1555.
184. Mann, D.M., Yates, P.O., Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech. Ageing Dev. 21 (1983), 193–203.
185. Mann, V.M., Cooper, J.M., Daniel, S.E., Srai, K., Jenner, P., Marsden, C.D., Schapira, A.H., Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36 (1994), 876–881.
186. Marsden, C.D., Neuromelanin and Parkinson's disease. J. Neural Transm. Suppl. 19 (1983), 121–141.
187. Martinez-Vicente, M., Vila, M., Alpha-synuclein and protein degradation pathways in Parkinson's disease: a pathological feed-back loop. Exp. Neurol. 247 (2013), 308–313.
188. Martinez-Vicente, M., Talloczy, Z., Kaushik, S., Massey, A.C., Mazzulli, J., Mosharov, E.V., Hodara, R., Fredenburg, R., Wu, D.C., Follenzi, A., Dauer, W., Przedborski, S., Ischiropoulos, H., Lansbury, P.T., Sulzer, D., Cuervo, A.M., Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Investig. 118 (2008), 777–788.
189. Mastroberardino, P.G., Hoffman, E.K., Horowitz, M.P., Betarbet, R., Taylor, G., Cheng, D., Na, H.M., Gutekunst, C.A., Gearing, M., Trojanowski, J.Q., Anderson, M., Chu, C.T., Peng, J., Greenamyre, J.T., A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol. Dis. 34 (2009), 417–431.
190. Mattammal, M.B., Strong, R., Lakshmi, V.M., Chung, H.D., Stephenson, A.H., Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J. Neurochem. 64 (1995), 1645–1654.
191. McGeer, P.L., Itagaki, S., Boyes, B.E., McGeer, E.G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988), 1285–1291.
192. McGinness, J.E., Mobility gaps: a mechanism for band gaps in melanins. Science 177 (1972), 896–897.
193. McGinness, J., Corry, P., Proctor, P., Amorphous semiconductor switching in melanins. Science 183 (1974), 853–855.
194. Melis, J.P., van Steeg, H., Luijten, M., Oxidative DNA damage and nucleotide excision repair. Antioxid. Redox Signal. 18 (2013), 2409–2419.
195. Mercado, G., Valdés, P., Hetz, C., An ERcentric view of Parkinson's disease. Trends Mol. Med. 19 (2013), 165–175.
196. Meredith, P., Sarna, T., The physical and chemical properties of eumelanin. Pigment Cell Res. 19 (2006), 572–594.
197. Meyer zum Gottesberge, A.M., Physiology and pathophysiology of inner ear melanin. Pigment Cell Res. 1 (1988), 238–249.
198. Mills, E., Dong, X.P., Wang, F., Xu, H., Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. Future Med. Chem. 2 (2010), 51–64.
199. Moos, T., Rosengren Nielsen, T., Skjørringe, T., Morgan, E.H., Iron trafficking inside the brain. J. Neurochem. 103 (2007), 1730–1740.
200. Morris, C.M., Edwardson, J.A., Iron histochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration 3 (1994), 277–282.
201. Mostert, A.B., Powell, B.J., Pratt, F.L., Hanson, G.R., Sarna, T., Gentle, I.R., Meredith, P., Role of semiconductivity and ion transport in the electrical conduction of melanin. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 8943–8947.
202. Muckenthaler, M.U., Galy, B., Hentze, M.W., Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu. Rev. Nutr. 28 (2008), 197–213.
203. Mullin, S., Schapira, A., α-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol. Neurobiol. 47 (2013), 587–597.
204. Muñoz, M., Villar, I., García-Erce, J.A., An update on iron physiology. World J. Gastroenterol. 15 (2009), 4617–4626.
205. Muñoz, P., Huenchuguala, S., Paris, I., Segura-Aguilar, J., Dopamine oxidation and autophagy. Park. Dis., 2012, 2012, 920953.
206. Muñoz, P., Paris, I., Sanders, L.H., Greenamyre, J.T., Segura-Aguilar, J., Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. Biochim. Biophys. Acta 1822 (2012), 1125–1136.
207. Muñoz, P., Cardenas, S., Huenchuguala, S., Briceño, A., Couve, E., Paris, I., Segura-Aguilar, J., DT-diaphorase prevents aminochrome-induced alpha-synuclein oligomer formation and neurotoxicity. Toxicol. Sci. 145 (2015), 37–47.
208. Napolitano, A., De Lucia, M., Panzella, L., d'Ischia, M., The “benzothiazine” chromophore of pheomelanins: a reassessment. Photochem. Photobiol. 84 (2008), 593–599.
209. Napolitano, A., Manini, P., d'Ischia, M., Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr. Med. Chem. 18 (2011), 1832–1845.
210. Norris, E.H., Giasson, B.I., Hodara, R., Xu, S., Trojanowski, J.Q., Ischiropoulos, H., Lee, V.M., Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280 (2005), 21212–21219.
211. Oberländer, U., Pletinckx, K., Döhler, A., Müller, N., Lutz, M.B., Arzberger, T., Riederer, P., Gerlach, M., Koutsilieri, E., Scheller, C., Neuromelanin is an immune stimulator for dendritic cells in vitro. BMC Neurosci., 12, 2011, 116.
212. Olivieri, S., Conti, A., Iannaccone, S., Cannistraci, C.V., Campanella, A., Barbariga, M., Codazzi, F., Pelizzoni, I., Magnani, G., Pesca, M., Franciotta, D., Cappa, S.F., Alessio, M., Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J. Neurosci. 31 (2011), 18568–18577.
213. Ortega, R., Cloetens, P., Devès, G., Carmona, A., Bohic, S., Iron storage within dopamine neurovesicles revealed by chemical nano-imaging. PLoS ONE, 2, 2007, e925.
214. Ostergren, A., Annas, A., Skog, K., Lindquist, N.G., Brittebo, E.B., Long-term retention of neurotoxic beta-carbolines in brain neuromelanin. J. Neural Transm. 111 (2004), 141–157.
215. Ott, M., Gogvadze, V., Orrenius, S., Zhivotovsky, B., Mitochondria, oxidative stress and cell death. Apoptosis 12 (2007), 913–922.
216. Pakkenberg, B., Møller, A., Gundersen, H.J., Mouritzen Dam, A., Pakkenberg, H., The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Psychiatry 54 (1991), 30–33.
217. Paris, I., Dagnino-Subiabre, A., Marcelain, K., Bennett, L.B., Caviedes, P., Caviedes, R., Azar, C.O., Segura-Aguilar, J., Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. J. Neurochem. 77 (2001), 519–529.
218. Paris, I., Martinez-Alvarado, P., Cárdenas, S., Perez-Pastene, C., Graumann, R., Fuentes, P., Olea-Azar, C., Caviedes, P., Segura-Aguilar, J., Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem. Res. Toxicol. 18 (2005), 415–419.
219. Paris, I., Martinez-Alvarado, P., Perez-Pastene, C., Vieira, M.N., Olea-Azar, C., Raisman-Vozari, R., Cardenas, S., Graumann, R., Caviedes, P., Segura-Aguilar, J., Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra. J. Neurochem. 92 (2005), 1021–1032.
220. Paris, I., Perez-Pastene, C., Cardenas, S., Iturriaga-Vasquez, P., Muñoz, P., Couve, E., Caviedes, P., Segura-Aguilar, J., Aminochrome induces disruption of actin, alpha-, and beta-tubulin cytoskeleton networks in substantia-nigra-derived cell line. Neurotox. Res. 18 (2010), 82–92.
221. Paris, I., Muñoz, P., Huenchuguala, S., Couve, E., Sanders, L.H., Greenamyre, J.T., Caviedes, P., Segura-Aguilar, J., Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line. Toxicol. Sci. 121 (2011), 376–388.
222. Park, R.M., Neurobehavioral deficits and parkinsonism in occupations with manganese exposure: a review of methodological issues in the epidemiological literature. Saf. Health Work 4 (2013), 123–135.
223. Peles, D.N., Hong, L., Hu, D.N., Ito, S., Nemanich, R.J., Simon, J.D., Human iridal stroma melanosomes of varying pheomelanin contents possess a common eumelanic outer surface. J. Phys. Chem. B 113 (2009), 11346–11351.
224. Perluigi, M., Coccia, R., Butterfield, D.A., 4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies. Antioxid. Redox Signal. 17 (2012), 1590–1609.
225. Pezzati, R., Bossi, M., Podini, P., Meldolesi, J., Grohovaz, F., High-resolution calcium mapping of the endoplasmic reticulum-Golgi-exocytic membrane system. Electron energy loss imaging analysis of quick frozen-freeze dried PC12 cells. Mol. Biol. Cell 8 (1997), 1501–1512.
226. Pilas, B., Sarna, T., Kalyanaraman, B., Swartz, H.M., The effect of melanin on iron associated decomposition of hydrogen peroxide. Free Radic. Biol. Med. 4 (1988), 285–293.
227. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, L.I., Nussbaum, R.L., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997), 2045–2047.
228. Prota, G., Melanins, melanogenesis and melanocytes: looking at their functional significance from the chemist's viewpoint. Pigment Cell Res. 13 (2000), 283–293.
229. Prota, G., Hu, D.N., Vincensi, M.R., McCormick, S.A., Napolitano, A., Characterization of melanins in human irides and cultured uveal melanocytes from eyes of different colors. Exp. Eye Res. 67 (1998), 293–299.
230. Quevedo, W.C. Jr., Holstein, T.J., General biology of mammalian pigmentation. Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.-P., (eds.) The Pigmentary System: Physiology and Pathophysiology, second edition, 2006, Blackwell Publishing, Malden, MA, USA, 63–90.
231. Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L.P., Goebel, I., Mubaidin, A.F., Wriekat, A.L., Roeper, J., Al-Din, A., Hillmer, A.M., Karsak, M., Liss, B., Woods, C.G., Behrens, M.I., Kubisch, C., Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38 (2006), 1184–1191.
232. Ramos, P., Santos, A., Pinto, N.R., Mendes, R., Magalhães, T., Almeida, A., Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes. J. Trace Elem. Med. Biol. 28 (2014), 13–17.
233. Rathore, K.I., Redensek, A., David, S., Iron homeostasis in astrocytes and microglia is differentially regulated by TNF-α and TGF-β1. Glia 60 (2012), 738–750.
234. Rice, M.E., Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci. 23 (2000), 209–216.
235. Riederer, P., Sofic, E., Rausch, W.D., Schmidt, B., Reynolds, G.P., Jellinger, K., Youdim, M.B., Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52 (1989), 515–520.
236. Rohn, T.T., Targeting alpha-synuclein for the treatment of Parkinson's disease. CNS Neurol. Disord. Drug Targets 11 (2012), 174–179.
237. Romeo, S., Viaggi, C., Di Camillo, D., Willis, A.W., Lozzi, L., Rocchi, C., Capannolo, M., Aloisi, G., Vaglini, F., Maccarone, R., Caleo, M., Missale, C., Racette, B.A., Corsini, G.U., Maggio, R., Bright light exposure reduces TH-positive dopamine neurons: implications of light pollution in Parkinson's disease epidemiology. Sci. Rep., 3, 2013, 1395.
238. Rosengren, E., Linder-Eliasson, E., Carlsson, A., Detection of 5-S-cysteinyldopamine in human brain. J. Neural Transm. 63 (1985), 247–253.
239. Rouault, T.A., Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis. Model Mech. 5 (2012), 155–164.
240. Rouault, T.A., Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat. Rev. Neurosci. 14 (2013), 551–564.
241. Rouault, T.A., Cooperman, S., Brain iron metabolism. Semin. Pediatr. Neurol. 13 (2006), 142–148.
242. Rouault, T.A., Zhang, D.L., Jeong, S.Y., Brain iron homeostasis, the choroid plexus, and localization of iron transport proteins. Metab. Brain Dis. 24 (2009), 673–684.
243. Rózanowska, M., Sarna, T., Land, E.J., Truscott, T.G., Free radical scavenging properties of melanin interaction of eu- and pheo-melanin models with reducing and oxidising radicals. Free Radic. Biol. Med. 26 (1999), 518–525.
244. Salazar, J., Mena, N., Hunot, S., Prigent, A., Alvarez-Fischer, D., Arredondo, M., Duyckaerts, C., Sazdovitch, V., Zhao, L., Garrick, L.M., Nuñez, M.T., Garrick, M.D., Raisman-Vozari, R., Hirsch, E.C., Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 18578–18583.
245. Salazar, M., Sokoloski, T.D., Patil, P.N., Binding of dopaminergic drugs by the neuromelanin of the substantia nigra, synthetic melanins and melanin granules. Fed. Proc. 37 (1978), 2403–2407.
246. Salonen, L.M., Ellermann, M., Diederich, F., Aromatic rings in chemical and biological recognition: energetics and structures. Angew. Chem. Int. Ed. Engl. 50 (2011), 4808–4842.
247. Sarna, T., Properties and function of the ocular melanin – a photobiophysical view. J. Photochem. Photobiol. B 12 (1992), 215–258.
248. Sarna, T., Swartz, H.M., The physical properties of melanins. Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.-P., (eds.) The Pigmentary System: Physiology and Pathophysiology, second edition, 2006, Blackwell Publishing, Malden, MA, USA, 311–341.
249. Sarna, T., Hyde, J.S., Swartz, H.M., Ion-exchange in melanin: an electron spin resonance study with lanthanide probes. Science 192 (1976), 1132–1134.
250. Sarna, T., Menon, I.A., Sealy, R.C., Photosensitization of melanins: a comparative study. Photochem. Photobiol. 42 (1985), 529–532.
251. Sarna, T., Burke, J.M., Korytowski, W., Rózanowska, M., Skumatz, C.M., Zareba, A., Zareba, M., Loss of melanin from human RPE with aging: possible role of melanin photooxidation. Exp. Eye Res. 76 (2003), 89–98.
252. Schubert, D., Chevion, M., The role of iron in beta amyloid toxicity. Biochem. Biophys. Res. Commun. 216 (1995), 702–707.
253. Schultzberg, M., Segura-Aguilar, J., Lind, C., Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies. Neuroscience 27 (1988), 763–776.
254. Scott, G.A., Melanosome trafficking and transfer. Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.-P., (eds.) The Pigmentary System: Physiology and Pathophysiology, second edition, 2006, Blackwell Publishing, Malden, MA, USA, 171–180.
255. Segura-Aguilar, J., Peroxidase activity of liver microsomal vitamin D 25-hydroxylase and cytochrome P450 1A2 catalyzes 25-hydroxylation of vitamin D3 and oxidation of dopamine to aminochrome. Biochem. Mol. Med. 58 (1996), 122–129.
256. Segura-Aguilar, J., Lind, C., On the mechanism of the Mn3(+)-induced neurotoxicity of dopamine:prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase. Chem. Biol. Interact. 72 (1989), 309–324.
257. Segura-Aguilar, J., Baez, S., Widersten, M., Welch, C.J., Mannervik, B., Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome. J. Biol. Chem. 272 (1997), 5727–5731.
258. Segura-Aguilar, J., Metodiewa, D., Welch, C.J., Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim. Biophys. Acta 1381 (1998), 1–6.
259. Segura-Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., Zucca, F.A., Protective and toxic roles of dopamine in Parkinson's disease. J. Neurochem. 129 (2014), 898–915.
260. Shen, X.M., Xia, B., Wrona, M.Z., Dryhurst, G., Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease. Chem. Res. Toxicol. 9 (1996), 1117–1126.
261. Shima, T., Sarna, T., Swartz, H.M., Stroppolo, A., Gerbasi, R., Zecca, L., Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic. Biol. Med. 23 (1997), 110–119.
262. Sian-Hülsmann, J., Mandel, S., Youdim, M.B., Riederer, P., The relevance of iron in the pathogenesis of Parkinson's disease. J. Neurochem. 118 (2011), 939–957.
263. Silvestri, L., Camaschella, C., A potential pathogenetic role of iron in Alzheimer's disease. J. Cell. Mol. Med. 12 (2008), 1548–1550.
264. Simon, J.D., Peles, D.N., The red and the black. Acc. Chem. Res. 43 (2010), 1452–1460.
265. Simon, J.D., Hong, L., Peles, D.N., Insights into melanosomes and melanin from some interesting spatial and temporal properties. J. Phys. Chem. B 112 (2008), 13201–13217.
266. Siraki, A.G., Smythies, J., O'Brien, P.J., Superoxide radical scavenging and attenuation of hypoxia-reoxygenation injury by neurotransmitter ferric complexes in isolated rat hepatocytes. Neurosci. Lett. 296 (2000), 37–40.
267. Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G.P., Hebenstreit, G., Youdim, M.B., Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74 (1988), 199–205.
268. Solano, F., Garcia-Borron, J.C., Enzymology of melanin formation. Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.-P., (eds.) The Pigmentary System: Physiology and Pathophysiology, second edition, 2006, Blackwell Publishing, Malden, MA, USA, 230–241.
269. Solomon, E.I., Heppner, D.E., Johnston, E.M., Ginsbach, J.W., Cirera, J., Qayyum, M., Kieber-Emmons, M.T., Kjaergaard, C.H., Hadt, R.G., Tian, L., Copper active sites in biology. Chem. Rev. 114 (2014), 3659–3853.
270. Sulzer, D., Zecca, L., Intraneuronal dopamine-quinone synthesis: a review. Neurotox. Res. 1 (2000), 181–195.
271. Sulzer, D., Surmeier, D.J., Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov. Disord. 28 (2013), 715–724.
272. Sulzer, D., Bogulavsky, J., Larsen, K.E., Behr, G., Karatekin, E., Kleinman, M.H., Turro, N., Krantz, D., Edwards, R.H., Greene, L.A., Zecca, L., Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 11869–11874.
273. Sulzer, D., Mosharov, E., Talloczy, Z., Zucca, F.A., Simon, J.D., Zecca, L., Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J. Neurochem. 106 (2008), 24–36.
274. Surmeier, D.J., Sulzer, D., The pathology roadmap in Parkinson disease. Prion 7 (2013), 85–91.
275. Takeda, K., Shibahara, S., Transcriptional regulation of melanocyte function. Nordlund, J.J., Boissy, R.E., Hearing, V.J., King, R.A., Oetting, W.S., Ortonne, J.-P., (eds.) The Pigmentary System: Physiology and Pathophysiology, second edition, 2006, Blackwell Publishing, Malden, MA, USA, 242–260.
276. Taly, A.B., Meenakshi-Sundaram, S., Sinha, S., Swamy, H.S., Arunodaya, G.R., Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 86 (2007), 112–121.
277. Tamarit, J., Gerez, C., Meier, C., Mulliez, E., Trautwein, A., Fontecave, M., The activating component of the anaerobic ribonucleotide reductase from Escherichia coli. An iron-sulfur center with only three cysteines. J. Biol. Chem. 275 (2000), 15669–15675.
278. Taylor, J.M., Main, B.S., Crack, P.J., Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem. Int. 62 (2013), 803–819.
279. Terland, O., Flatmark, T., Tangerås, A., Grønberg, M., Dopamine oxidation generates an oxidative stress mediated by dopamine semiquinone and unrelated to reactive oxygen species. J. Mol. Cell Cardiol. 29 (1997), 1731–1738.
280. Theil, E.C., Le Brun, N.E., Fe transport and storage related to humans and pathogens and oxygen. Reedijk, J., Poeppelmeier, K.R., (eds.) Comprehensive Inorganic Chemistry II, vol. 3, 2013, Elsevier, 21–33.
281. Thompson, C.M., Capdevila, J.H., Strobel, H.W., Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid. J. Pharmacol. Exp. Ther. 294 (2000), 1120–1130.
282. Tiekink, E.R.T., Zukerman-Schpector, J., (eds.) The Importance of Pi-Interactions in Crystal Engineering: Frontiers in Crystal Engineering, 2012, John Wiley & Sons.
283. Todorich, B., Pasquini, J.M., Garcia, C.I., Paez, P.M., Connor, J.R., Oligodendrocytes and myelination: the role of iron. Glia 57 (2009), 467–478.
284. Tomter, A.B., Zoppellaro, G., Andersen, N.H., Hersleth, H.P., Hammerstad, M., Røhr, A.K., Sandvik, G.K., Strand, K.R., Nilsson, G.E., Bell, C.B. III, Barra, A.L., Blasco, E., Le Pape, L., Solomon, E.I., Andersson, K.K., Ribonucleotide reductase class I with different radical generating clusters. Coord. Chem. Rev. 257 (2013), 3–26.
285. Tribl, F., Arzberger, T., Riederer, P., Gerlach, M., Tyrosinase is not detected in human catecholaminergic neurons by immunohistochemistry and Western blot analysis. J. Neural Transm. Suppl. 72 (2007), 51–55.
286. Trinh, J., Farrer, M., Advances in the genetics of Parkinson disease. Nat. Rev. Neurol. 9 (2013), 445–454.
287. Tse, D.C., McCreery, R.L., Adams, R.N., Potential oxidative pathways of brain catecholamines. J. Med. Chem. 19 (1976), 37–40.
288. Turnbull, S., Tabner, B.J., El-Agnaf, O.M., Moore, S., Davies, Y., Allsop, D., alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic. Biol. Med. 30 (2001), 1163–1170.
289. Urrutia, P., Aguirre, P., Esparza, A., Tapia, V., Mena, N.P., Arredondo, M., González-Billault, C., Núñez, M.T., Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J. Neurochem. 126 (2013), 541–549.
290. Uversky, V.N., Li, J., Fink, A.L., Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276 (2001), 44284–44296.
291. Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A.R., Healy, D.G., Albanese, A., Nussbaum, R., González-Maldonado, R., Deller, T., Salvi, S., Cortelli, P., Gilks, W.P., Latchman, D.S., Harvey, R.J., Dallapiccola, B., Auburger, G., Wood, N.W., Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004), 1158–1160.
292. Van Laar, V.S., Mishizen, A.J., Cascio, M., Hastings, T.G., Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol. Dis. 34 (2009), 487–500.
293. Viceconte, N., Burguillos, M.A., Herrera, A.J., De Pablos, R.M., Joseph, B., Venero, J.L., Neuromelanin activates proinflammatory microglia through a caspase-8-dependent mechanism. J. Neuroinflamm., 12, 2015, 5.
294. Volles, M.J., Lansbury, P.T. Jr., Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41 (2002), 4595–4602.
295. Wakamatsu, K., Ito, S., Advanced chemical methods in melanin determination. Pigment Cell Res. 15 (2002), 174–183.
296. Wakamatsu, K., Fujikawa, K., Zucca, F.A., Zecca, L., Ito, S., The structure of neuromelanin as studied by chemical degradative methods. J. Neurochem. 86 (2003), 1015–1023.
297. Wakamatsu, K., Hu, D.N., McCormick, S.A., Ito, S., Characterization of melanin in human iridal and choroidal melanocytes from eyes with various colored irides. Pigment Cell Melanoma Res. 21 (2008), 97–105.
298. Wakamatsu, K., Murase, T., Zucca, F.A., Zecca, L., Ito, S., Biosynthetic pathway to neuromelanin and its aging process. Pigment Cell Melanoma Res. 25 (2012), 792–803.
299. Wakamatsu, K., Tanaka, H., Tabuchi, K., Ojika, M., Zucca, F.A., Zecca, L., Ito, S., Reduction of the nitro group to amine by hydroiodic acid to synthesize o-aminophenol derivatives as putative degradative markers of neuromelanin. Molecules 19 (2014), 8039–8050.
300. Ward, R.J., Zucca, F.A., Duyn, J.H., Crichton, R.R., Zecca, L., The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 13 (2014), 1045–1060.
301. Ward, W.C., Guan, Z., Zucca, F.A., Fariello, R.G., Kordestani, R., Zecca, L., Raetz, C.R., Simon, J.D., Identification and quantification of dolichol and dolichoic acid in neuromelanin from substantia nigra of the human brain. J. Lipid Res. 48 (2007), 1457–1462.
302. Westlund, K.N., Denney, R.M., Kochersperger, L.M., Rose, R.M., Abell, C.W., Distinct monoamine oxidase A and B populations in primate brain. Science 230 (1985), 181–183.
303. Whitehead, R.E., Ferrer, J.V., Javitch, J.A., Justice, J.B., Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J. Neurochem. 76 (2001), 1242–1251.
304. Wielgus, A.R., Sarna, T., Melanin in human irides of different color and age of donors. Pigment Cell Res. 18 (2005), 454–464.
305. Williams, A., MPTP parkinsonism. Br. Med. J. (Clin. Res. Ed.) 289 (1984), 1401–1402.
306. Williams, R., Buchheit, C.L., Berman, N.E., LeVine, S.M., Pathogenic implications of iron accumulation in multiple sclerosis. J. Neurochem. 120 (2012), 7–25.
307. Wilms, H., Rosenstiel, P., Sievers, J., Deuschl, G., Zecca, L., Lucius, R., Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J. 17 (2003), 500–502.
308. Windahl, M.S., Petersen, C.R., Christensen, H.E., Harris, P., Crystal structure of tryptophan hydroxylase with bound amino acid substrate. Biochemistry 47 (2008), 12087–12094.
309. Wolters, E.C.H., Braak, H., Parkinson's disease: premotor clinico-pathological correlations. J. Neural Transm. Suppl. 70 (2006), 309–319.
310. Wypijewska, A., Galazka-Friedman, J., Bauminger, E.R., Wszolek, Z.K., Schweitzer, K.J., Dickson, D.W., Jaklewicz, A., Elbaum, D., Friedman, A., Iron and reactive oxygen species activity in parkinsonian substantia nigra. Parkinsonism Relat. Disord. 16 (2010), 329–333.
311. Xiong, R., Siegel, D., Ross, D., Quinone-induced protein handling changes: implications for major protein handling systems in quinone-mediated toxicity. Toxicol. Appl. Pharmacol. 280 (2014), 285–295.
312. Xu, J., Jia, Z., Knutson, M.D., Leeuwenburgh, C., Impaired iron status in aging research. Int. J. Mol. Sci. 13 (2012), 2368–2386.
313. Xu, Y., Stokes, A.H., Roskoski, R. Jr., Vrana, K.E., Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J. Neurosci. Res. 54 (1998), 691–697.
314. Yamamoto, A., Shin, R.W., Hasegawa, K., Naiki, H., Sato, H., Yoshimasu, F., Kitamoto, T., Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J. Neurochem. 82 (2002), 1137–1147.
315. Ye, T., Simon, J.D., Sarna, T., Ultrafast energy transfer from bound tetra(4-N,N,N,N-trimethylanilinium)porphyrin to synthetic dopa and cysteinyldopa melanins. Photochem. Photobiol. 77 (2003), 1–4.
316. Youdim, M.B., Ben-Shachar, D., Yehuda, S., Putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior. Am. J. Clin. Nutr. 50 (1989), 607–615 (discussion 615–617).
317. Youdim, M.B., Edmondson, D., Tipton, K.F., The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7 (2006), 295–309.
318. Zadlo, A., Rozanowska, M.B., Burke, J.M., Sarna, T.J., Photobleaching of retinal pigment epithelium melanosomes reduces their ability to inhibit iron-induced peroxidation of lipids. Pigment Cell Res. 20 (2007), 52–60.
319. Zadlo, A., Burke, J.M., Sarna, T., Effect of untreated and photobleached bovine RPE melanosomes on the photoinduced peroxidation of lipids. Photochem. Photobiol. Sci. 8 (2009), 830–837.
320. Zafar, K.S., Siegel, D., Ross, D., A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol. Pharmacol. 70 (2006), 1079–1086.
321. Zajac, G.W., Gallas, J.M., Cheng, J., Eisner, M., Moss, S.C., Alvarado-Swaisgood, A.E., The fundamental unit of synthetic melanin: a verification by tunneling microscopy of X-ray scattering results. Biochim. Biophys. Acta 1199 (1994), 271–278.
322. Zareba, M., Bober, A., Korytowski, W., Zecca, L., Sarna, T., The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochim. Biophys. Acta 1271 (1995), 343–348.
323. Zareba, M., Skumatz, C.M., Sarna, T.J., Burke, J.M., Photic injury to cultured RPE varies among individual cells in proportion to their endogenous lipofuscin content as modulated by their melanosome content. Investig. Ophthalmol. Vis. Sci. 55 (2014), 4982–4990.
324. Zecca, L., Swartz, H.M., Total and paramagnetic metals in human substantia nigra and its neuromelanin. J. Neural Transm. Park. Dis. Dement. Sect. 5 (1993), 203–213.
325. Zecca, L., Mecacci, C., Seraglia, R., Parati, E., The chemical characterization of melanin contained in substantia nigra of human brain. Biochim. Biophys. Acta 1138 (1992), 6–10.
326. Zecca, L., Pietra, R., Goj, C., Mecacci, C., Radice, D., Sabbioni, E., Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J. Neurochem. 62 (1994), 1097–1101.
327. Zecca, L., Shima, T., Stroppolo, A., Goj, C., Battiston, G.A., Gerbasi, R., Sarna, T., Swartz, H.M., Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 73 (1996), 407–415.
328. Zecca, L., Costi, P., Mecacci, C., Ito, S., Terreni, M., Sonnino, S., Interaction of human substantia nigra neuromelanin with lipids and peptides. J. Neurochem. 74 (2000), 1758–1765.
329. Zecca, L., Gallorini, M., Schünemann, V., Trautwein, A.X., Gerlach, M., Riederer, P., Vezzoni, P., Tampellini, D., Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76 (2001), 1766–1773.
330. Zecca, L., Tampellini, D., Costi, P., Rizzio, E., Giaveri, G., Gallorini, M., Combined biochemical separation and INAA for the determination of iron and other metals in neuromelanin of human brain substantia nigra. J. Radioanal. Nucl. Chem. 249 (2001), 449–454.
331. Zecca, L., Tampellini, D., Rizzio, E., Giaveri, G., Gallorini, M., The determination of iron and other metals by INAA in cortex, cerebellum and putamen of human brain and in their neuromelanins. J. Radioanal. Nucl. Chem. 248 (2001), 129–131.
332. Zecca, L., Fariello, R., Riederer, P., Sulzer, D., Gatti, A., Tampellini, D., The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett. 510 (2002), 216–220.
333. Zecca, L., Zucca, F.A., Wilms, H., Sulzer, D., Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci. 26 (2003), 578–580.
334. Zecca, L., Youdim, M.B., Riederer, P., Connor, J.R., Crichton, R.R., Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5 (2004), 863–873.
335. Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G., Arosio, P., Santambrogio, P., Fariello, R.G., Karatekin, E., Kleinman, M.H., Turro, N., Hornykiewicz, O., Zucca, F.A., The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 9843–9848.
336. Zecca, L., Casella, L., Albertini, A., Bellei, C., Zucca, F.A., Engelen, M., Zadlo, A., Szewczyk, G., Zareba, M., Sarna, T., Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J. Neurochem. 106 (2008), 1866–1875.
337. Zecca, L., Bellei, C., Costi, P., Albertini, A., Monzani, E., Casella, L., Gallorini, M., Bergamaschi, L., Moscatelli, A., Turro, N.J., Eisner, M., Crippa, P.R., Ito, S., Wakamatsu, K., Bush, W.D., Ward, W.C., Simon, J.D., Zucca, F.A., New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 17567–17572.
338. Zecca, L., Wilms, H., Geick, S., Claasen, J.H., Brandenburg, L.O., Holzknecht, C., Panizza, M.L., Zucca, F.A., Deuschl, G., Sievers, J., Lucius, R., Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol. 116 (2008), 47–55.
339. Zhang, W., Phillips, K., Wielgus, A.R., Liu, J., Albertini, A., Zucca, F.A., Faust, R., Qian, S.Y., Miller, D.S., Chignell, C.F., Wilson, B., Jackson-Lewis, V., Przedborski, S., Joset, D., Loike, J., Hong, J.S., Sulzer, D., Zecca, L., Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox. Res. 19 (2011), 63–72.
340. Zhang, W., Zecca, L., Wilson, B., Ren, H.W., Wang, Y.J., Wang, X.M., Hong, J.S., Human neuromelanin: an endogenous microglial activator for dopaminergic neuron death. Front. Biosci. (Elite Ed.) 5 (2013), 1–11.
341. Zhou, Z.D., Lim, T.M., Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones. Free Radic. Res. 43 (2009), 417–430.
342. Zhou, Z.D., Lan, Y.H., Tan, E.K., Lim, T.M., Iron species-mediated dopamine oxidation, proteasome inhibition, and dopaminergic cell demise: implications for iron-related dopaminergic neuron degeneration. Free Radic. Biol. Med. 49 (2010), 1856–1871.
343. Zucca, F.A., Bellei, C., Giannelli, S., Terreni, M.R., Gallorini, M., Rizzio, E., Pezzoli, G., Albertini, A., Zecca, L., Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J. Neural Transm. 113 (2006), 757–767.
344. Zucca, F.A., Cupaioli, F.A., Zecca, L., The role of iron in neurodegeneration. Milardi, D., Rizzarelli, E., (eds.) Neurodegeneration: Metallostasis and Proteostasis, 2011, RSC Publishing, Cambridge, 174–211.
345. Zucca, F.A., Basso, E., Cupaioli, F.A., Ferrari, E., Sulzer, D., Casella, L., Zecca, L., Neuromelanin of the human substantia nigra: an update. Neurotox. Res. 25 (2014), 13–23.